Medicinal herbs for hepatitis C virus infection (Review)

Background Hepatitis C virus (HCV) infection is a serious health problem world-wide. Medicinal herbs are increasingly being used for hepatitis C. Objectives To assess the eHicacy and safety of medicinal herbs for hepatitis C virus infection. Search methods Searches were applied to The Controlled Trial Registers of The Cochrane Hepato-Biliary Group, The Cochrane Complementary Medicine Field, and The Cochrane Library as well as MEDLINE, EMBASE, BIOSIS, Chinese and Japanese databases (February 2001). Five Chinese and one Japanese journals were handsearched. No language restriction was used. Selection criteria Randomised clinical trials comparing medicinal herbs versus placebo, no intervention, general non-specific treatment, other herbal medicine, or interferon and/or ribavirin treatment. Trials of medicinal herbs plus interferon and/or ribavirin versus interferon and/or ribavirin alone were also included. Data collection and analysis Two authors extracted data independently. The methodological quality of the trials was evaluated using the generation of allocation sequence, allocation concealment, double blinding, and the Jadad-scale. The outcomes were presented as relative risk or weighted mean diHerence, both with 95% confidence interval. Main results Ten randomised trials, including 517 patients with mainly chronic hepatitis C, evaluated ten diHerent medicinal herbs versus various control interventions (four placebo, four interferon, two other herbs). The methodological quality was considered adequate in four trials and inadequate in six trials. Compared with placebo in four trials, none of the medicinal herbs showed positive eHects on clearance of serum HCV RNA or anti-HCV antibody or on serum liver enzymes, except one short-term trial in which a silybin preparation showed a significant eHect on reducing serum aspartate aminotransferase and gamma-glutamyltranspeptidase activities. The herbal compound Bing Gan Tang combined with interferon-alpha showed significantly better eHects on clearance of serum HCV RNA (relative risk 2.54; 95% confidence interval 1.43 to 4.49) and on normalisation of serum alanine aminotransferase activity (relative risk 2.54; 95% confidence interval 1.43 to 4.49) than interferon-alpha monotherapy. The herbal compound Yi Zhu decoction showed a significant eHect on clearance Medicinal herbs for hepatitis C virus infection (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 1 Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews of serum HCV RNA and normalisation of ALT levels compared to glycyrrhizin plus ribavirin. Yi Er Gan Tang showed a significant eHect on normalising serum alanine aminotransferase compared to silymarin plus glucurolactone. There was no significant eHicacy of the other examined herbs. The herbs were associated with adverse events. Authors' conclusions There is no firm evidence of eHicacy of any medicinal herbs for HCV infection. Medicinal herbs for HCV infection should not be used outside randomised clinical trials. P L A I N L A N G U A G E S U M M A R Y Still awaiting evidence on e4icacy of medicinal herbs for viral hepatitis C Hepatitis C is an infectious disease of the liver caused by hepatitis C virus. Around 170 million people world-wide are chronically infected with this virus. The infection is associated with severe sequelae such as liver cirrhosis, liver cancer, or liver failure. Herbal medicines have been used for treating hepatitis C. This systematic review evaluates the eHects of herbal medicines for treating acute and chronic hepatitis C infection. Ten diHerent herbal medicines were tested in ten randomised trials in patients with chronic hepatitis C. The present systematic review found no significant antiviral eHect of the herbal medicines when compared with placebo, but the data suggest that some herbal medicines in combination with interferon may have eHects on the clearance of HCV RNA and on normalisation of liver enzymes. However, there is no strong evidence for any eHicacy of these medicinal herbs for chronic hepatitis C due to the fact that most positive eHects came from clinical trials with low methodological quality. Medicinal herbs for hepatitis C virus infection should not be used outside well-designed, randomised clinical trials. Medicinal herbs for hepatitis C virus infection (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2 Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews

[1]  N. Méndez-Sánchez [Epidemiology of hepatitis C]. , 2002, Revista de gastroenterologia de Mexico.

[2]  Christian Gluud,et al.  Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.

[3]  Jianpin Liu,et al.  Medicinal herbs for hepatitis C virus infection. , 2001, The Cochrane database of systematic reviews.

[4]  G. Farrell Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know , 2000, Journal of gastroenterology and hepatology.

[5]  J. Chan,et al.  Toxicity of Complementary Therapies: An Eastern Perspective , 2000, Journal of clinical pharmacology.

[6]  Bao-en Wang,et al.  Treatment of chronic liver diseases with traditional Chinese medicine , 2000, Journal of gastroenterology and hepatology.

[7]  L. Seeff,et al.  45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.

[8]  R. Kohnen,et al.  Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. , 1999, BMJ.

[9]  D. Schuppan,et al.  Herbal products for liver diseases: A therapeutic challenge for the new millennium , 1999, Hepatology.

[10]  K. Linde,et al.  Liver enzyme elevations in patients treated with traditional Chinese medicine. , 1999, JAMA.

[11]  D. Vlahov,et al.  Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection , 1999, Hepatology.

[12]  V. Rogiers,et al.  Sho‐saiko‐to: The right blend of traditional oriental medicine and liver cell biology , 1999, Hepatology.

[13]  R. Kessler,et al.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.

[14]  K. Kemper,et al.  A review of 12 commonly used medicinal herbs. , 1998, Archives of family medicine.

[15]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[16]  A. Vickers,et al.  Do certain countries produce only positive results? A systematic review of controlled trials. , 1998, Controlled clinical trials.

[17]  J. Hoofnagle,et al.  Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.

[18]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[19]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[20]  T. Ishizaki,et al.  Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. , 1996, The European respiratory journal.

[21]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[22]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[23]  C. Gil,et al.  Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.

[24]  Richard E. Sampliner,et al.  The Natural History of Community-Acquired Hepatitis C in the United States , 1993 .

[25]  R. Purcell,et al.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. , 1991, The New England journal of medicine.

[26]  B. Schneider,et al.  Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. , 1989, Journal of hepatology.

[27]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[28]  R. D. de Man,et al.  Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. , 1998, Alimentary pharmacology & therapeutics.